AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2064515
Drug: Vitamin-K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-K antagonists and dipyridamole
Trial: 2064515
Drug: Vitamin-K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-K antagonists and placebo
Trial: 27245042
Drug: Jingui Shenqi
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jingui Shenqi pill combined with nifedipine sustained-release tablets
Trial: 16715189
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg methylprednisolone (Group I)
Trial: 3894216
Drug: Butoconazole nitrate
RxNorm normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butoconazole nitrate cream (3-day course)
Trial: 3894216
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate cream (7-day course)
Trial: 21397284
Drug: Partially hydrogenated
RxNorm normalized name: SOY OIL,PARTIALLY HYDROGENATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrogenated soybean oil (15 g/d TFA)
Trial: 10719945
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (tranexamic acid with autologous blood collection, n = 32)
Trial: 10719945
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (saline infusion, n = 43)
Trial: 7504977
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of aprotinin
Trial: 7504977
Drug: Classical doses
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical doses of aprotinin
Trial: 3797115
Drug: Natural human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural human surfactant (60 mg surfactant/kg body weight)
Trial: 27436880
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment arm
Trial: 23551243
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral vitamin D3 supplementation (2000 IU per day for 30 days)
Trial: 23551243
Drug: Simulated summer
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated summer UV exposure (10 sunbed sessions to a total dose of 23.8 SED)
Trial: 23551243
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (oral vitamin D3 and UV exposure)
Trial: 23551243
Drug: Whole-body sunbed
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body sunbed exposure (4.8 SED twice weekly)
Trial: 19501354
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg triptorelin (group A; n=172)
Trial: 16681719
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m(2) on day 1 and gemcitabine 1250 mg/m(2) on days 1 and 8, sequence T‐‐>G
Trial: 16681719
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2)
Trial: 16681719
Drug: Gemcitabine 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1250 mg/m(2) and paclitaxel 150 mg/m(2)
Trial: 16681719
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2) with sequence G‐‐>T
Trial: 12809965
Drug: Statin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin use (1892 patients, 21.9% of total); mean TC level of 5.99 mmol/L (231.6 mg/dL) at end of study; 1096 patients (57.9%) had TC levels above cutoff.
Trial: 12809965
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin use (6761 patients, 78.1% of total); mean TC level of 6.24 mmol/L (241.4 mg/dL) at end of study; 5316 patients (78.6%) had TC levels above cutoff.
Trial: 11182393
Drug: Subareolar injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subareolar injection of technetium‐99 sulfur colloid and blue dye
Trial: 11182393
Drug: Peritumoral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritumoral injection of technetium‐99 sulfur colloid and blue dye
Trial: 2496149
Drug: Fluvoxamine, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine, 100 mg daily for 17 days
Trial: 2496149
Drug: Clovoxamine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clovoxamine, 150 mg daily for 17 days
Trial: 323023
Drug: Tolamolol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolamolol (300 mg/day - 900 mg/day)
Trial: 323023
Drug: Methyldopa (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (750 mg/day - 2250 mg/day)
Trial: 26682608
Drug: 8-week gross
RxNorm normalized name: OSTERICUM GROSSESERRATUM ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week gross motor skills program (10 min. daily)
Trial: 24135213
Drug: E‐couch program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E‐couch program (unguided Web‐based program based on cognitive behavioral therapy and interpersonal therapy)
Trial: 20605477
Drug: Mandibular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular nerve block (MNB) with 5 mL ropivacaine 0.5% for each block
Trial: 18348597
Drug: memantine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: memantine 20 mg/day
Trial: 17146409
Drug: m-CPP 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-CPP 0.5 mg/kg
Trial: 7943920
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of triazolam p.o.
Trial: 29988111
Drug: Catumaxomab followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catumaxomab followed by chemotherapy (FLOT)
Trial: 25188566
Drug: Dynamic interpersonal
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic interpersonal group psychotherapy (DIGP), 16 sessions held weekly
Trial: 10521742
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (20 mg)
Trial: 8928194
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (topical nasal drop of 0.1% betamethasone for 12 patients and oral administration of prednisolone for 5 patients)
Trial: 6388588
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g glucose load with 50 g ethanol
Trial: 6388588
Drug: Starch solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch solution (maize meal) and alcohol
Trial: 25060690
Drug: Low-dose ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose ethanol intervention
Trial: 22235808
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus 12 weekly music therapy sessions delivered by the Northern Ireland Music Therapy Trust
Trial: 11895049
Drug: Lovastatin alone
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin alone administered with dinner
Trial: 8544722
Drug: CFM (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFM (480 ml)
Trial: 8544722
Drug: RM (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RM (480 ml)
Trial: 7002830
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Mianserin
Trial: 7002830
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg Mianserin
Trial: 7002830
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg Mianserin
Trial: 12145434
Drug: Fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaric acid ester (FAE) tablets (Fumaderm) with increasing daily dosage from 105 to 1,075 mg + calcipotriol ointment (50 microg/g), applied twice daily
Trial: 12145434
Drug: Fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaric acid ester (FAE) tablets (Fumaderm) with increasing daily dosage from 105 to 1,075 mg + ointment vehicle
Trial: 3143482
Drug: Ergotamine tartrate
RxNorm normalized name: Ergotamine Tartrate
DrugBank: Ergotamine (DB00696)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergotamine tartrate compound
Trial: 29488226
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg Q2W
Trial: 25594355
Drug: Gel with
RxNorm normalized name: GEL WITH PUMP (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel with active substances (hyaluronic acid, sericin, glycerol, urea)
Trial: 16514482
Drug: IL-2 (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 (11 x 10(6) IU subcutaneously on days 1-4, 8-11, and 15-18 of every 28-day cycle) + Bryostatin-1 (5, 15, or 25 mcg/m2 on days 1, 8, and 15 starting in the second cycle)
Trial: 16514482
Drug: IL-2 (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 (11 x 10(6) IU subcutaneously on days 1-4, 8-11, and 15-18 of every 28-day cycle) + Bryostatin-1 (35 mcg/m2, non-randomized)
Trial: 6661620
Drug: Minocycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (200 mg)
Trial: 6661620
Drug: Ampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (500 mg)
Trial: 22173570
Drug: Dexmedetomidine 0.1
RxNorm normalized name: dexmedetomidine 0.12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.1 μg/kg/min for 10 min loading dose, followed by 0.4 μg/kg/h continuous infusion
Trial: 22173570
Drug: Propofol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.1 mg/kg/min for 10 min loading dose, followed by 1 mg/kg/h continuous infusion
Trial: 19906800
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Ca/d
Trial: 19906800
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg Ca/d
Trial: 12628633
Drug: no‐treatment control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no‐treatment control condition (n = 10)
Trial: 7632029
Drug: diltiazem-trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem-trimetazidine (60 mg/24 h)
Trial: 30074327
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg of clonidine with hyperbaric bupivacaine (BC15 group)
Trial: 30074327
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg of clonidine with hyperbaric bupivacaine (BC30 group)
Trial: 30074327
Drug: 60 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 μg of clonidine with hyperbaric bupivacaine (BC60 group)
Trial: 25682602
Drug: Prednisone 1
RxNorm normalized name: prednisone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 1 mg/kg/day for grade IIa manifestations
Trial: 25682602
Drug: Prednisone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 0.5 mg/kg/day for grade IIa manifestations
Trial: 25682602
Drug: Prednisone 2
RxNorm normalized name: prednisone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 2 mg/kg/day for grade IIb or higher manifestations
Trial: 25682602
Drug: Prednisone 1
RxNorm normalized name: prednisone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 1 mg/kg/day for grade IIb or higher manifestations
Trial: 20454943
Drug: Standard-dose ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ganciclovir (5 mg/kg twice daily for 1 week)
Trial: 20454943
Drug: Low-dose ganciclovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ganciclovir (5 mg/kg twice daily for 1 week)
Trial: 20454943
Drug: Standard-dose ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ganciclovir
Trial: 20454943
Drug: Low-dose ganciclovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ganciclovir
Trial: 12019196
Drug: Rofecoxib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (125 mg, 100 micro Ci) in healthy subjects
Trial: 12019196
Drug: Rofecoxib (142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (142 mg, 100 micro Ci) in cholecystectomy patients
Trial: 7621843
Drug: Salbutamol CR
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol CR 8 mg b.i.d.
Trial: 23154577
Drug: Postprandial exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial exercise (walking on a motorized treadmill at ca. 50%V(·)o(2)max for 30 min) after glucose with OFTT cream intake
Trial: 21632504
Drug: Id vaccine
RxNorm normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Id vaccine (Id-KLH + GM-CSF)
Trial: 21632504
Drug: IgM-Id vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-Id vaccine
Trial: 21632504
Drug: IgG-Id vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG-Id vaccine
Trial: 19098687
Drug: 25 mg/d
RxNorm normalized name: fluoride 0.25 mg/drop oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/d of dehydroepiandrosterone
Trial: 17101607
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g amino acids, 1.2 g glycerol, and 0.5 g fat emulsion/kg/day (approximately 15 kcal/kg/day)
Trial: 17101607
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g amino acids, 1.5 g dextrose, and 0.5 g fat emulsion/kg/day (approximately 15 kcal/kg/day)
Trial: 3602843
Drug: Ivermectin (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (100, 150, and 200 mcg/kg)
Trial: 24598116
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution
Trial: 20006290
Drug: Anma therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anma therapy (40-min session)
Trial: 18200453
Drug: Probatory CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probatory CPAP therapy with follow-up examination
Trial: 18200453
Drug: Immediate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate prescription of CPAP device
Trial: 18200453
Drug: Probatory CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probatory CPAP therapy
Trial: 12575587
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy combined with anti-tumor drugs
Trial: 3475036
Drug: Enoxacin 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 600 mg, single dose
Trial: 3475036
Drug: Enoxacin 400
RxNorm normalized name: enoxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 400 mg, single dose
Trial: 3475036
Drug: Enoxacin 400
RxNorm normalized name: enoxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 400 mg every 12 h, four doses
Trial: 3475036
Drug: All enoxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enoxacin doses
Trial: 30597504
Drug: 2-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g oral TXA 2 hours pre-operatively followed by 1-g oral TXA 3 hours post-operatively (group B)
Trial: 30597504
Drug: 2-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g oral TXA followed by 1-g oral TXA 3 and 7 hours post-operatively (group C)
Trial: 30597504
Drug: 2-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g oral TXA followed by 1-g oral TXA 3, 7 and 11 hours post-operatively (group D)
Trial: 30597504
Drug: 2-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g oral TXA followed by 1-g oral TXA 3, 7, 11 and 15 hours post-operatively (group E)
Trial: 22565161
Drug: Once-daily MMX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily MMX mesalamine 2.4 g/day
Trial: 22565161
Drug: Twice-daily delayed-release
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily delayed-release mesalamine 1.6 g/day
Trial: 19838864
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection (2 ml lidocaine of 1%)
Trial: 18058494
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg at Week 0 and 40 mg every other week from Week 1 to Week 15
Trial: 11747061
Drug: Relaxation training
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation training offered independently of medical treatment
Trial: 9205767
Drug: ebrotidine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebrotidine 400 mg/day
Trial: 9205767
Drug: ebrotidine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebrotidine 800 mg/day
Trial: 9205767
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg/day
Trial: 9205767
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg/day
Trial: 7970506
Drug: Taxol 135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol 135 mg/m2
Trial: 7970506
Drug: Taxol 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol 175 mg/m2
Trial: 3620002
Drug: Initial test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial test administration (Beck and Zung scales)
Trial: 30508645
Drug: Serum 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25-hydroxyvitamin D levels categorized in four groups: <25.0, 25.0-49.9, 50.0-74.9, and ≥75.0 nmol/L (highest group as reference)
Trial: 28287413
Drug: Fructose Supplement
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose Supplement (FS)
Trial: 28287413
Drug: Glucose Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose Supplement (GS)
Trial: 24483106
Drug: Shenling Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenling Fuzheng Capsule (SFC) or Qingdu Capsule (QC)
Trial: 24483106
Drug: SFC or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC or QC combined with highly active antiretroviral agents
Trial: 19903376
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of aspirin
Trial: 19903376
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day of aspirin
Trial: 17011743
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of semantic fluency and narrative recall
Trial: 15491387
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of enalapril and losartan (Group A)
Trial: 11080322
Drug: Thermoluminescent dosimeter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermoluminescent dosimeter (TLD) measurements of radiation dose to the skin and whole body over the lead apron.
Trial: 11080322
Drug: Thermoluminescent dosimeter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermoluminescent dosimeter (TLD) measurements of radiation dose to the whole body under the lead apron.
Trial: 30062709
Drug: Quercetin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 1,000 mg/day for 12 weeks
Trial: 27501900
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ULDCT) (100 kVp ± 20 and 10 mAs)
Trial: 27501900
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (LDCT) (100 kVp and 60 mAs)
Trial: 20578205
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (1.34 g/kg body weight)
Trial: 20578205
Drug: Conventional protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional protein diet (0.8 g/kg body weight)